Elevance Health (NYSE:ELV) on Thursday issued its preliminary financial results for Q1 2025, projecting $9.61 of GAAP net income and $11.97 of non-GAAP net income on a diluted per share basis, exceeding $11.38 projected by analysts.
In a regulatory filing